Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01141101 · ClinicalTrials.gov registry record
Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus
A clinical trial of Methicillin-resistant Staphylococcus Aureus, sponsored by Boston Medical Center.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT01141101 is a study of Methicillin-resistant Staphylococcus Aureus that has completed, run by Boston Medical Center. The registered enrollment target is 100 participants, below the 15,885-participant average among 5 other Methicillin-resistant Staphylococcus Aureus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01141101, a study of Methicillin-resistant Staphylococcus Aureus, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The prevalence of Methicillin-resistant Staphylococcus aureus (MRSA) colonization and infections have been increasing in the general population, including the pediatric population. It has been reported that MRSA colonization persists for up to four years, and therefore the youngest pediatric patients, specifically those who are less than 2 years of age, have a high risk of prolonged colonization during a period of time when they are susceptible to significant skin and soft tissue infections (SSTIs) attributable to MRSA. Once prolonged colonization takes place, recurrent SSTIs are commonplace, resulting in substantial morbidity and in some cases mortality, as well as a significant cost to the healthcare system. Individuals colonized with MRSA have an increased risk of developing MRSA infections, which range from mild disease, such as carbuncles, to severe infections, such as necrotizing pneumonia and toxic shock syndrome. The prevalence of severe MRSA infections is also greatest in neonates and infants, where increased MRSA colonization has been observed. In the early infant period, the most common manifestation of MRSA disease is pustular skin lesions, which affect approximately 5% of the general population, with MRSA-colonization being a major risk factor for this disease. Moreover, the prevalence of pustular disease is increasing in the general population, and there are numerous case reports of invasive, life-threatening MRSA disease in the early infant period. Corresponding to the increasing prevalence in the community, the carriage of MRSA in pregnant women has also escalated, and vaginal carriage is significant in pregnant women. As an analogy, maternal vaginal Group B Streptococcal (GBS) colonization is the major risk for infant colonization regardless of whether early or late neonatal colonization or disease occurs. It is quite feasible that vaginal MRSA carriage predisposes newborns to colonization during the birthing process; however, this mechanism has no
Conditions Studied
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01141101
The ClinicalTrials.gov registry entry for NCT01141101 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 15,885-participant average among 5 other Methicillin-resistant Staphylococcus Aureus trials with a reported enrollment target (99% lower). The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Methicillin-resistant Staphylococcus Aureus appearing as the primary indexed condition, and to 0 interventions.
NCT01141101 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01141101 about?
NCT01141101 is a clinical study titled "Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus". The prevalence of Methicillin-resistant Staphylococcus aureus (MRSA) colonization and infections have been increasing in the general population, including the pediatric population. It has been reported that MRSA colonization persists for up to four years, and therefore the youngest pediatric patient...
What is the current status of trial NCT01141101?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2010-06. Estimated completion is 2012-06.
What conditions does trial NCT01141101 study?
This clinical trial studies the following conditions: Methicillin-resistant Staphylococcus Aureus.
Who is sponsoring clinical trial NCT01141101?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01141101 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methicillin-resistant Staphylococcus Aureus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PMT for MDRO Decolonization
RECRUITING · Phase 2
-
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
RECRUITING · Phase 4
-
Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)
COMPLETED · NA
-
Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms
COMPLETED
-
Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.